Inactive pharmaceutical ingredients : implications for pregnancy.
Finkelstein
Yaron
Y
The Motherisk Program, Division of Clinical Pharmacology & Toxicology, The Hospital for Sick Children, Toronto, Canada.
Rezvani
Massoud
M
Garcia-Bournissen
Facundo
F
Nurmohamed
Laila
L
Koren
Gideon
G
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000517:prevention & control; D000277:Adjuvants, Pharmaceutic / Q000009:adverse effects* / Q000145:classification*; D002170:Canada; D004339:Drug Compounding; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D019344:Lactic Acid / Q000009:adverse effects; D019800:Phenol / Q000009:adverse effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects; D018570:Risk Assessment; D012439:Saccharin / Q000009:adverse effects
D000277:Adjuvants, Pharmaceutic; D011409:Propylene Glycols; D019800:Phenol; D019344:Lactic Acid; D012439:Saccharin